Strides Arcolab Ltd and Eli Lilly have announced a collaboration to expand the delivery of cancer medicines in the emerging markets.
As part of this arrangement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialities division of Strides Arcolab, based in Bangalore.
Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these medications in multiple geographies across the emerging markets.
In addition to the initial 10 medicines included as part of the agreement, Eli Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future.
Jacques Tapiero, Lilly Senior Vice-President and President of its emerging markets division, said: “Cancer medicines of the highest quality continue to be an unmet need in many markets around the world. Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets.”
Arun Kumar, Founder & Group CEO of Strides Arcolab, said: “We are delighted to partner with Lilly to expand its branded generics platform with high-quality oncology products that will benefit from Lilly’s strong global presence in key markets.”